Skip to content
value.today

Decibel Therapeutics, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2013
Total raised
$87 M
2 rounds on record
Latest round
$55 M
Nov 2020
First round on record
Oct 2015
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Decibel Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2020$55 MNo. 2$50 to $250 million

Decibel Therapeutics, Inc.: Raise no. 2, Nov 2020

Investors in this round

23 investors had bought by the notice of Nov 12, 2020: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 22 investors are named for Decibel Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$55 M of $82 M offered; $27 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elisabeth Leiderman · Executive Officer
  • Laurence Reid · Executive Officer, Director
  • Anthony A. Philippakis · Director
  • Christine A. Poon · Director
  • Neil A. Exter · Director
  • Peter A. Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Laurence Reid, PhD, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 12, 2020. Read the notice at the SEC.

equitySEC
Oct 2015$32 MNo. 1$10 to $50 million

Decibel Therapeutics, Inc.: Raise no. 1, Oct 2015

Investors in this round

3 investors had bought by the notice of Jan 13, 2017: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 22 investors are named for Decibel Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$32 M of $58 M offered; $25 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John J. Keilty · Executive Officer
  • Steven H. Holtzman · Executive Officer, Director
  • Craig H. Muir · Director
  • George H. Scangos · Director
  • Jeffrey H. Jonas · Director
  • Jens H. Eckstein · Director
  • Kevin Starr · Director
  • Roger H. Brown · Director
  • Troy H. Brennan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven H. Holtzman, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 13, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Decibel Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2020).

    SEC Form D · Nov 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2020

That is all the official record says: Decibel Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

22 named in official filings. Open an investor to see everything it has backed.

Investors in Decibel Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Casdin Partners Master Fund, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GSK PLCFund or asset managernot statednot statedHeld Series A, C and D preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
GV 2016 GP, L.L.C.Othernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2016 GP, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2016, L.P.Fund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2017 GP, L.L.C.Othernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2017 GP, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2017, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2019 GP, L.L.C.Othernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2019 GP, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GV 2019, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Longevity Fund 2 LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
OrbiMed Capital GP VIII LLCFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Orbimed Capital LLCFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
OrbiMed Genesis GP LLCOthernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Regeneron Pharmaceuticals, Inc.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Schroder Adveq cPl Global Management III L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Schroder Adveq Management Luxembourg SarlFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Third Rock Ventures GP III, L.P.Venture capitalnot statednot statedHeld Series A, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Third Rock Ventures III, L.P.Venture capitalnot statednot statedHeld Series A, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
TRV GP III, LLCOthernot statednot statedHeld Series A, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 23 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Decibel Therapeutics, Inc.
NameRoleNamed in
Elisabeth LeidermanExecutive officerNov 2020
Laurence ReidExecutive officerNov 2020
John J. KeiltyExecutive officerJan 2017
Steven H. HoltzmanExecutive officerJan 2017
Kevin StarrExecutive officerOct 2015
Michael SolomonExecutive officerOct 2015
Anthony A. PhilippakisDirectorNov 2020
Christine A. PoonDirectorNov 2020
Laurence ReidDirectorNov 2020
Neil A. ExterDirectorNov 2020
Peter A. ThompsonDirectorNov 2020
Craig H. MuirDirectorJan 2017
George H. ScangosDirectorJan 2017
Jeffrey H. JonasDirectorJan 2017
Jens H. EcksteinDirectorJan 2017
Kevin StarrDirectorJan 2017
Roger H. BrownDirectorJan 2017
Steven H. HoltzmanDirectorJan 2017
Troy H. BrennanDirectorJan 2017
Craig MuirDirectorOct 2015
Jens EcksteinDirectorOct 2015